Search

Purpose: To conduct a comprehensive narrative review of the evidence for radiotherapy target volumes to the neck, after neck dissection, for head and neck squamous cell carcinoma from an unknown primary (HNSCCUP). Inclusion or exclusion of mucosal irradiation is not the focus of interest for this review article. Materials and Methods: Literature (PubMed‐Medline, EMBASE database and Cochrane library) was searched using the relevant keywords. The search results were limited to the studies published in year 2000 or after. Results: Eight studies met the inclusion criteria. All studies were retrospective in nature. The incidence of contralateral recurrence rates in the untreated neck when the involved neck only is treated remains very low (0%–10%). Survival has improved over the past two decades, most likely due to improved diagnostic techniques and the increase in incidence of HPV‐related disease. Conclusion: Given the rarity of disease, level one evidence from randomised controlled trials is lacking. Available data are retrospective but support unilateral post‐operative radiotherapy as a treatment option in selected cases. [ABSTRACT FROM AUTHOR]

This article presents the findings of a study on the use of reactive nasogastric tube (NGT) feeding in patients with head and neck cancer (HNC) undergoing radiotherapy. The study found that most patients admitted for NGT feeding were receiving curative radiotherapy. The timing of NGT insertion varied, and the study suggests that streamlining access to NGT feeding could reduce hospital stays. The article also discusses the cost implications of NGT feeding and suggests that an outpatient NGT feeding service could be beneficial in initiating earlier enteral feeding and avoiding hospital admissions. [Extracted from the article]

The introduction of immunotherapy into the radical management of head and neck cancer (HNC) is a fast moving phenomenon, which is constantly developing. Although now established in the management of recurrent and metastatic disease in HNC, its use in radical treatment is being investigated in a whole spectrum of clinical trials looking at which immune altering agents give the best results, which can be added safely to radiotherapy, chemotherapy, and chemoradiotherapy for greatest efficiency and when the most appropriate time to add these agents is in the neoadjuvant, concurrent on adjuvant settings. These multiple questions produce a complex matrix for HNC investigators and this article brings together the existing evidence and contemporary trials going on with immunotherapy in HNC, giving an up to date snapshot of present investigations and near future directions for further research. [ABSTRACT FROM AUTHOR]